سعر سيبري بريزهيلر 50 مكجم 2026

Seebri Breezhaler is a Novartis long-acting muscarinic antagonist (glycopyrronium 50 micrograms per capsule) supplied in Egypt as 30 inhalation capsules with a Breezhaler inhaler for once-daily COPD maintenance.

• Maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).Population: Adultselectronic medicines compendium (emc), UK

• Most common anticholinergic reaction is dry mouth (2.4%); also urinary retention (uncommon), gastroenteritis, dyspepsia, throat irritation, nasopharyngitis, rhinitis and sinusitis.International label, same product · electronic medicines compendium (emc), UK

• Hypersensitivity to glycopyrronium or to any of the excipients (capsules contain lactose).International label, same product · electronic medicines compendium (emc), UK

• Not for acute use or rescue therapy of bronchospasm; stop if hypersensitivity reactions or paradoxical bronchospasm occur.International label, same product · electronic medicines compendium (emc), UK
• Use with caution in narrow-angle glaucoma or urinary retention; patients should stop treatment and seek help if signs of acute narrow-angle glaucoma develop.International label, same product · electronic medicines compendium (emc), UK

• Other anticholinergic-containing medicinesCo-administration has not been studied and is not recommended.electronic medicines compendium (emc), UK

• No data in pregnant women; animal studies do not indicate harmful effects; use only if the expected benefit justifies the potential risk to the foetus.International label, same product · electronic medicines compendium (emc), UK
• Unknown whether excreted in human milk (excreted in rat milk); consider use only if the expected benefit to the woman outweighs any possible risk to the infant.International label, same product · electronic medicines compendium (emc), UK

• Glycopyrronium: Blocks muscarinic M3 receptors on airway smooth muscle, causing bronchodilation.